UAE biosimulation product outlook (Revenue, USD million, 2021-2033)
- Software
- Molecular Modeling & Simulation Software
- Docking, molecular dynamics, QSAR
- In-silico ADME (e.g., ChemAxon-type tools)
- Large Pharma (Top -30)
- Mid Pharma (30-300)
- Emerging / Long-tail Pharma & Biotech
- Physicochemical property prediction (logP, pKa, solubility, permeability)
- Clinical Trial Design Software
- Clinical trial simulation
- Adaptive design
- Virtual patients
- Dose optimization
- MIDD-linked applications
- PK/PD Modeling & Simulation Software
- Compartmental modeling
- Population PK/PD (Pop PK/PD)
- Non-compartmental analysis (NCA)
- Dose-response, bioequivalence
- PBPK Modeling & Simulation Software
- ADME (mechanistic)
- DDI modeling
- FIH dose prediction
- Special populations
- Toxicity Prediction Software
- Hepatotoxicity, cardiotoxicity, genotoxicity
- QSAR, mechanistic, AI/ML models
- ADME-linked toxicity
- QSP / Systems Biology Software
- Mechanistic disease modeling
- Multi-scale simulation
- Integration with PBPK
- Other Biosimulation Software
- AI-driven platforms
- RWD-integrated tools
- Services
- Contract Services
- PK/PD services
- Pop PK/PD
- NCA
- Compartmental
- PBPK services
- ADME
- DDI
- Special populations
- Consulting Services
- Large Pharma (Top -30)
- Mid Pharma (30-300)
- Emerging / Long-tail Pharma & Biotech
- Implementation, Training & Support
- Deployment
- Integration
- Training
